The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Bi-Specific MAbS Market Research Report 2024

Global Bi-Specific MAbS Market Research Report 2024

Publishing Date : May, 2024

License Type :
 

Report Code : 1998381

No of Pages : 98

Ask Your Query
Synopsis
Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.
The global Bi-Specific MAbS market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Bi-Specific MAbS is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bi-Specific MAbS is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Bi-Specific MAbS in Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Bi-Specific MAbS include Johnson and Johnson, Novartis AG, Hoffmann-La Roche Ltd., Chugai Pharmaceutical, Bayer AG, Thermo Fisher Scientific, Bistro-Myers Squibb, Mylan N.V. and Daiichi Sankyo Company, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bi-Specific MAbS, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific MAbS.
Report Scope
The Bi-Specific MAbS market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bi-Specific MAbS market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bi-Specific MAbS companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson and Johnson
Novartis AG
Hoffmann-La Roche Ltd.
Chugai Pharmaceutical
Bayer AG
Thermo Fisher Scientific
Bistro-Myers Squibb
Mylan N.V.
Daiichi Sankyo Company
Abbott
AstraZeneca
Eli Lilly
Merck and Co.
Amgen
Pfizer
GlaxoSmithKline plc
Roche
Segment by Type
Catumaxomab
Blinatumomab
Duligotumab
SAR 156597
Segment by Application
Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Microbial Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bi-Specific MAbS companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bi-Specific MAbS Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Catumaxomab
1.2.3 Blinatumomab
1.2.4 Duligotumab
1.2.5 SAR 156597
1.3 Market by Application
1.3.1 Global Bi-Specific MAbS Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Autoimmune Diseases
1.3.4 Inflammatory Diseases
1.3.5 Infectious Diseases
1.3.6 Microbial Diseases
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bi-Specific MAbS Market Perspective (2019-2030)
2.2 Bi-Specific MAbS Growth Trends by Region
2.2.1 Global Bi-Specific MAbS Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Bi-Specific MAbS Historic Market Size by Region (2019-2024)
2.2.3 Bi-Specific MAbS Forecasted Market Size by Region (2025-2030)
2.3 Bi-Specific MAbS Market Dynamics
2.3.1 Bi-Specific MAbS Industry Trends
2.3.2 Bi-Specific MAbS Market Drivers
2.3.3 Bi-Specific MAbS Market Challenges
2.3.4 Bi-Specific MAbS Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bi-Specific MAbS Players by Revenue
3.1.1 Global Top Bi-Specific MAbS Players by Revenue (2019-2024)
3.1.2 Global Bi-Specific MAbS Revenue Market Share by Players (2019-2024)
3.2 Global Bi-Specific MAbS Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bi-Specific MAbS Revenue
3.4 Global Bi-Specific MAbS Market Concentration Ratio
3.4.1 Global Bi-Specific MAbS Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bi-Specific MAbS Revenue in 2023
3.5 Bi-Specific MAbS Key Players Head office and Area Served
3.6 Key Players Bi-Specific MAbS Product Solution and Service
3.7 Date of Enter into Bi-Specific MAbS Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bi-Specific MAbS Breakdown Data by Type
4.1 Global Bi-Specific MAbS Historic Market Size by Type (2019-2024)
4.2 Global Bi-Specific MAbS Forecasted Market Size by Type (2025-2030)
5 Bi-Specific MAbS Breakdown Data by Application
5.1 Global Bi-Specific MAbS Historic Market Size by Application (2019-2024)
5.2 Global Bi-Specific MAbS Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Bi-Specific MAbS Market Size (2019-2030)
6.2 North America Bi-Specific MAbS Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Bi-Specific MAbS Market Size by Country (2019-2024)
6.4 North America Bi-Specific MAbS Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bi-Specific MAbS Market Size (2019-2030)
7.2 Europe Bi-Specific MAbS Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Bi-Specific MAbS Market Size by Country (2019-2024)
7.4 Europe Bi-Specific MAbS Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bi-Specific MAbS Market Size (2019-2030)
8.2 Asia-Pacific Bi-Specific MAbS Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Bi-Specific MAbS Market Size by Region (2019-2024)
8.4 Asia-Pacific Bi-Specific MAbS Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Bi-Specific MAbS Market Size (2019-2030)
9.2 Latin America Bi-Specific MAbS Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Bi-Specific MAbS Market Size by Country (2019-2024)
9.4 Latin America Bi-Specific MAbS Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bi-Specific MAbS Market Size (2019-2030)
10.2 Middle East & Africa Bi-Specific MAbS Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Bi-Specific MAbS Market Size by Country (2019-2024)
10.4 Middle East & Africa Bi-Specific MAbS Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson and Johnson
11.1.1 Johnson and Johnson Company Detail
11.1.2 Johnson and Johnson Business Overview
11.1.3 Johnson and Johnson Bi-Specific MAbS Introduction
11.1.4 Johnson and Johnson Revenue in Bi-Specific MAbS Business (2019-2024)
11.1.5 Johnson and Johnson Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Bi-Specific MAbS Introduction
11.2.4 Novartis AG Revenue in Bi-Specific MAbS Business (2019-2024)
11.2.5 Novartis AG Recent Development
11.3 Hoffmann-La Roche Ltd.
11.3.1 Hoffmann-La Roche Ltd. Company Detail
11.3.2 Hoffmann-La Roche Ltd. Business Overview
11.3.3 Hoffmann-La Roche Ltd. Bi-Specific MAbS Introduction
11.3.4 Hoffmann-La Roche Ltd. Revenue in Bi-Specific MAbS Business (2019-2024)
11.3.5 Hoffmann-La Roche Ltd. Recent Development
11.4 Chugai Pharmaceutical
11.4.1 Chugai Pharmaceutical Company Detail
11.4.2 Chugai Pharmaceutical Business Overview
11.4.3 Chugai Pharmaceutical Bi-Specific MAbS Introduction
11.4.4 Chugai Pharmaceutical Revenue in Bi-Specific MAbS Business (2019-2024)
11.4.5 Chugai Pharmaceutical Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Detail
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Bi-Specific MAbS Introduction
11.5.4 Bayer AG Revenue in Bi-Specific MAbS Business (2019-2024)
11.5.5 Bayer AG Recent Development
11.6 Thermo Fisher Scientific
11.6.1 Thermo Fisher Scientific Company Detail
11.6.2 Thermo Fisher Scientific Business Overview
11.6.3 Thermo Fisher Scientific Bi-Specific MAbS Introduction
11.6.4 Thermo Fisher Scientific Revenue in Bi-Specific MAbS Business (2019-2024)
11.6.5 Thermo Fisher Scientific Recent Development
11.7 Bistro-Myers Squibb
11.7.1 Bistro-Myers Squibb Company Detail
11.7.2 Bistro-Myers Squibb Business Overview
11.7.3 Bistro-Myers Squibb Bi-Specific MAbS Introduction
11.7.4 Bistro-Myers Squibb Revenue in Bi-Specific MAbS Business (2019-2024)
11.7.5 Bistro-Myers Squibb Recent Development
11.8 Mylan N.V.
11.8.1 Mylan N.V. Company Detail
11.8.2 Mylan N.V. Business Overview
11.8.3 Mylan N.V. Bi-Specific MAbS Introduction
11.8.4 Mylan N.V. Revenue in Bi-Specific MAbS Business (2019-2024)
11.8.5 Mylan N.V. Recent Development
11.9 Daiichi Sankyo Company
11.9.1 Daiichi Sankyo Company Company Detail
11.9.2 Daiichi Sankyo Company Business Overview
11.9.3 Daiichi Sankyo Company Bi-Specific MAbS Introduction
11.9.4 Daiichi Sankyo Company Revenue in Bi-Specific MAbS Business (2019-2024)
11.9.5 Daiichi Sankyo Company Recent Development
11.10 Abbott
11.10.1 Abbott Company Detail
11.10.2 Abbott Business Overview
11.10.3 Abbott Bi-Specific MAbS Introduction
11.10.4 Abbott Revenue in Bi-Specific MAbS Business (2019-2024)
11.10.5 Abbott Recent Development
11.11 AstraZeneca
11.11.1 AstraZeneca Company Detail
11.11.2 AstraZeneca Business Overview
11.11.3 AstraZeneca Bi-Specific MAbS Introduction
11.11.4 AstraZeneca Revenue in Bi-Specific MAbS Business (2019-2024)
11.11.5 AstraZeneca Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Detail
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Bi-Specific MAbS Introduction
11.12.4 Eli Lilly Revenue in Bi-Specific MAbS Business (2019-2024)
11.12.5 Eli Lilly Recent Development
11.13 Merck and Co.
11.13.1 Merck and Co. Company Detail
11.13.2 Merck and Co. Business Overview
11.13.3 Merck and Co. Bi-Specific MAbS Introduction
11.13.4 Merck and Co. Revenue in Bi-Specific MAbS Business (2019-2024)
11.13.5 Merck and Co. Recent Development
11.14 Amgen
11.14.1 Amgen Company Detail
11.14.2 Amgen Business Overview
11.14.3 Amgen Bi-Specific MAbS Introduction
11.14.4 Amgen Revenue in Bi-Specific MAbS Business (2019-2024)
11.14.5 Amgen Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Detail
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Bi-Specific MAbS Introduction
11.15.4 Pfizer Revenue in Bi-Specific MAbS Business (2019-2024)
11.15.5 Pfizer Recent Development
11.16 GlaxoSmithKline plc
11.16.1 GlaxoSmithKline plc Company Detail
11.16.2 GlaxoSmithKline plc Business Overview
11.16.3 GlaxoSmithKline plc Bi-Specific MAbS Introduction
11.16.4 GlaxoSmithKline plc Revenue in Bi-Specific MAbS Business (2019-2024)
11.16.5 GlaxoSmithKline plc Recent Development
11.17 Roche
11.17.1 Roche Company Detail
11.17.2 Roche Business Overview
11.17.3 Roche Bi-Specific MAbS Introduction
11.17.4 Roche Revenue in Bi-Specific MAbS Business (2019-2024)
11.17.5 Roche Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Bi-Specific MAbS Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Catumaxomab
Table 3. Key Players of Blinatumomab
Table 4. Key Players of Duligotumab
Table 5. Key Players of SAR 156597
Table 6. Global Bi-Specific MAbS Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Bi-Specific MAbS Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Bi-Specific MAbS Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Bi-Specific MAbS Market Share by Region (2019-2024)
Table 10. Global Bi-Specific MAbS Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Bi-Specific MAbS Market Share by Region (2025-2030)
Table 12. Bi-Specific MAbS Market Trends
Table 13. Bi-Specific MAbS Market Drivers
Table 14. Bi-Specific MAbS Market Challenges
Table 15. Bi-Specific MAbS Market Restraints
Table 16. Global Bi-Specific MAbS Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Bi-Specific MAbS Market Share by Players (2019-2024)
Table 18. Global Top Bi-Specific MAbS Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific MAbS as of 2023)
Table 19. Ranking of Global Top Bi-Specific MAbS Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Bi-Specific MAbS Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Bi-Specific MAbS Product Solution and Service
Table 23. Date of Enter into Bi-Specific MAbS Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Bi-Specific MAbS Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Bi-Specific MAbS Revenue Market Share by Type (2019-2024)
Table 27. Global Bi-Specific MAbS Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Bi-Specific MAbS Revenue Market Share by Type (2025-2030)
Table 29. Global Bi-Specific MAbS Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Bi-Specific MAbS Revenue Market Share by Application (2019-2024)
Table 31. Global Bi-Specific MAbS Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Bi-Specific MAbS Revenue Market Share by Application (2025-2030)
Table 33. North America Bi-Specific MAbS Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Bi-Specific MAbS Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Bi-Specific MAbS Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Bi-Specific MAbS Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Bi-Specific MAbS Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Bi-Specific MAbS Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Bi-Specific MAbS Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Bi-Specific MAbS Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Bi-Specific MAbS Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Bi-Specific MAbS Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Bi-Specific MAbS Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Bi-Specific MAbS Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Bi-Specific MAbS Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Bi-Specific MAbS Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Bi-Specific MAbS Market Size by Country (2025-2030) & (US$ Million)
Table 48. Johnson and Johnson Company Detail
Table 49. Johnson and Johnson Business Overview
Table 50. Johnson and Johnson Bi-Specific MAbS Product
Table 51. Johnson and Johnson Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 52. Johnson and Johnson Recent Development
Table 53. Novartis AG Company Detail
Table 54. Novartis AG Business Overview
Table 55. Novartis AG Bi-Specific MAbS Product
Table 56. Novartis AG Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 57. Novartis AG Recent Development
Table 58. Hoffmann-La Roche Ltd. Company Detail
Table 59. Hoffmann-La Roche Ltd. Business Overview
Table 60. Hoffmann-La Roche Ltd. Bi-Specific MAbS Product
Table 61. Hoffmann-La Roche Ltd. Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 62. Hoffmann-La Roche Ltd. Recent Development
Table 63. Chugai Pharmaceutical Company Detail
Table 64. Chugai Pharmaceutical Business Overview
Table 65. Chugai Pharmaceutical Bi-Specific MAbS Product
Table 66. Chugai Pharmaceutical Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 67. Chugai Pharmaceutical Recent Development
Table 68. Bayer AG Company Detail
Table 69. Bayer AG Business Overview
Table 70. Bayer AG Bi-Specific MAbS Product
Table 71. Bayer AG Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 72. Bayer AG Recent Development
Table 73. Thermo Fisher Scientific Company Detail
Table 74. Thermo Fisher Scientific Business Overview
Table 75. Thermo Fisher Scientific Bi-Specific MAbS Product
Table 76. Thermo Fisher Scientific Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 77. Thermo Fisher Scientific Recent Development
Table 78. Bistro-Myers Squibb Company Detail
Table 79. Bistro-Myers Squibb Business Overview
Table 80. Bistro-Myers Squibb Bi-Specific MAbS Product
Table 81. Bistro-Myers Squibb Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 82. Bistro-Myers Squibb Recent Development
Table 83. Mylan N.V. Company Detail
Table 84. Mylan N.V. Business Overview
Table 85. Mylan N.V. Bi-Specific MAbS Product
Table 86. Mylan N.V. Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 87. Mylan N.V. Recent Development
Table 88. Daiichi Sankyo Company Company Detail
Table 89. Daiichi Sankyo Company Business Overview
Table 90. Daiichi Sankyo Company Bi-Specific MAbS Product
Table 91. Daiichi Sankyo Company Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 92. Daiichi Sankyo Company Recent Development
Table 93. Abbott Company Detail
Table 94. Abbott Business Overview
Table 95. Abbott Bi-Specific MAbS Product
Table 96. Abbott Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 97. Abbott Recent Development
Table 98. AstraZeneca Company Detail
Table 99. AstraZeneca Business Overview
Table 100. AstraZeneca Bi-Specific MAbS Product
Table 101. AstraZeneca Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 102. AstraZeneca Recent Development
Table 103. Eli Lilly Company Detail
Table 104. Eli Lilly Business Overview
Table 105. Eli Lilly Bi-Specific MAbS Product
Table 106. Eli Lilly Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 107. Eli Lilly Recent Development
Table 108. Merck and Co. Company Detail
Table 109. Merck and Co. Business Overview
Table 110. Merck and Co. Bi-Specific MAbS Product
Table 111. Merck and Co. Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 112. Merck and Co. Recent Development
Table 113. Amgen Company Detail
Table 114. Amgen Business Overview
Table 115. Amgen Bi-Specific MAbS Product
Table 116. Amgen Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 117. Amgen Recent Development
Table 118. Pfizer Company Detail
Table 119. Pfizer Business Overview
Table 120. Pfizer Bi-Specific MAbS Product
Table 121. Pfizer Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 122. Pfizer Recent Development
Table 123. GlaxoSmithKline plc Company Detail
Table 124. GlaxoSmithKline plc Business Overview
Table 125. GlaxoSmithKline plc Bi-Specific MAbS Product
Table 126. GlaxoSmithKline plc Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 127. GlaxoSmithKline plc Recent Development
Table 128. Roche Company Detail
Table 129. Roche Business Overview
Table 130. Roche Bi-Specific MAbS Product
Table 131. Roche Revenue in Bi-Specific MAbS Business (2019-2024) & (US$ Million)
Table 132. Roche Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Bi-Specific MAbS Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Bi-Specific MAbS Market Share by Type: 2023 VS 2030
Figure 3. Catumaxomab Features
Figure 4. Blinatumomab Features
Figure 5. Duligotumab Features
Figure 6. SAR 156597 Features
Figure 7. Global Bi-Specific MAbS Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Bi-Specific MAbS Market Share by Application: 2023 VS 2030
Figure 9. Cancer Case Studies
Figure 10. Autoimmune Diseases Case Studies
Figure 11. Inflammatory Diseases Case Studies
Figure 12. Infectious Diseases Case Studies
Figure 13. Microbial Diseases Case Studies
Figure 14. Others Case Studies
Figure 15. Bi-Specific MAbS Report Years Considered
Figure 16. Global Bi-Specific MAbS Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Bi-Specific MAbS Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Bi-Specific MAbS Market Share by Region: 2023 VS 2030
Figure 19. Global Bi-Specific MAbS Market Share by Players in 2023
Figure 20. Global Top Bi-Specific MAbS Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific MAbS as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Bi-Specific MAbS Revenue in 2023
Figure 22. North America Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Bi-Specific MAbS Market Share by Country (2019-2030)
Figure 24. United States Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Bi-Specific MAbS Market Share by Country (2019-2030)
Figure 28. Germany Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Bi-Specific MAbS Market Share by Region (2019-2030)
Figure 36. China Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Bi-Specific MAbS Market Share by Country (2019-2030)
Figure 44. Mexico Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Bi-Specific MAbS Market Share by Country (2019-2030)
Figure 48. Turkey Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Bi-Specific MAbS Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Johnson and Johnson Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 51. Novartis AG Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 52. Hoffmann-La Roche Ltd. Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 53. Chugai Pharmaceutical Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 54. Bayer AG Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 55. Thermo Fisher Scientific Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 56. Bistro-Myers Squibb Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 57. Mylan N.V. Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 58. Daiichi Sankyo Company Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 59. Abbott Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 60. AstraZeneca Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 61. Eli Lilly Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 62. Merck and Co. Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 63. Amgen Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 64. Pfizer Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 65. GlaxoSmithKline plc Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 66. Roche Revenue Growth Rate in Bi-Specific MAbS Business (2019-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock